BEF, Author at The Boomer Esiason Foundation

March 19, 2019

Source: Science Daily (July 31, 2012) Cystic fibrosis is an inherited disease caused by mutations in a gene that adversely affect its protein product. In its correct form and cellular location, this protein, cystic fibrosis transmembrane conductance regulator (CFTR), functions as a channel for ions to...

Final Results from Phase 2 Combination Study of Kalydeco and VX-809 Show Significant Improvements

by BEF

CF Community, CF News, Research, Therapies

March 19, 2019

Source: Cystic Fibrosis Foundation A Phase 2 clinical trial of Kalydeco™ in combination with VX-809 showed significant improvements in lung function in people with the most common CF mutation, according to final results announced today by Vertex Pharmaceuticals Inc. Both Kalydeco and VX-809, a CF drug in...

Concentrated Saline Therapy Not Effective in Young Children with CF, Study Finds

by BEF

CF News, Research, Therapies

March 19, 2019

Inhaling concentrated saline (salt water) mist does not reduce how often infants and young children with cystic fibrosis need antibiotics for respiratory symptoms, according to findings from a clinical trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes...

New Website Offers Insight on Cystic Fibrosis Gene Mutations

by BEF

CF Community, CF News, Research

March 19, 2019

Source: Cystic Fibrosis Foundation A major international research effort has led to a new online resource — www.CFTR2.org — that provides information about specific cystic fibrosis gene mutations to people with CF and their families, researchers, health professionals and the general public. The project is a collaboration...

New Clues for Improving Antibiotics for Tolerant Bacteria

by BEF

CF News, Research

March 19, 2019

Source: Scientific American The superbug MRSA (methicillin-resistant Staphylococcus aureus) has provoked fear in doctors and patients alike because it is endowed with genetic characteristics that make it impervious to many antibiotics, and it can be deadly to boot. Less well known, however, is another class of...

Genzyme and CFFT Announce Collaboration to Discover New CF Drugs

by BEF

CF News, Research

March 19, 2019

Genzyme, a Sanofi company, and Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508. People...

Agile Sciences Gets NIH Grant to Study Treatment for Lung Infections

by BEF

CF News, Research

March 19, 2019

The National Institutes of Health (NIH) has awarded Agile Sciences a Phase I STTR Grant to evaluate the efficacy of Agile Sciences’ proprietary Agilyte™ anti-biofilm molecules for treating lung infections of cystic fibrosis patients. The molecules will be tested in a new model of chronic...

Most Parents Unaware of Medical Research Opportunities for Their Kids

by BEF

CF Community, CF News, Research

March 19, 2019

Note: For information about clinical trials related to cystic fibrosis research, please visit our Research page. Eighty-four percent of parents say they don't know about opportunities for their children to participate in medical research; only 5 percent of children have participated in medical research across the...

Changes in Lung Stem Cells May Contribute to CF Progression

by BEF

CF News, Research

March 19, 2019

Researchers at the University of Iowa's Roy J. and Lucille A. Carver College of Medicine have discovered that in cystic fibrosis (CF) patients, the airway glands are depleted of a specific population of airway stem cells that participate in airway repair following injury. Their results are...

Battle of the Bugs: Pseudomonas Breaches Cell Wall of Rival Bacteria Without Hurting Itself

by BEF

CF News, Research

March 19, 2019

Microbiologists have uncovered a sneaky trick by the bacterium Pseudomonas aeruginosa to oust rivals. It deploys a toxin delivery machine to breach cell walls of competitors without hurting itself. Its means of attack helps it survive in the outside environment and may even help it...

Author: BEF

Gene Network Restores Cystic Fibrosis Protein Function

Final Results from Phase 2 Combination Study of Kalydeco and VX-809 Show Significant Improvements

Concentrated Saline Therapy Not Effective in Young Children with CF, Study Finds

New Website Offers Insight on Cystic Fibrosis Gene Mutations

New Clues for Improving Antibiotics for Tolerant Bacteria

Genzyme and CFFT Announce Collaboration to Discover New CF Drugs

Agile Sciences Gets NIH Grant to Study Treatment for Lung Infections

Most Parents Unaware of Medical Research Opportunities for Their Kids

Changes in Lung Stem Cells May Contribute to CF Progression

Battle of the Bugs: Pseudomonas Breaches Cell Wall of Rival Bacteria Without Hurting Itself

Never miss an update. Subscribe to our emails!